Presentation ESC 2022

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Presenter: John H. Alexander

August 28, 2022

REGISTER for free or LOG IN to view this content

Efficacy and Safety of the Oral Factor XIa Inhibitor, Asundexian, Added to Dual Antiplatelet Therapy After an Acute Myocardial Infarction

Coronary

CAD Pharma

ACS/AMI

Presentation

ESC 2022

Up Next

Presentation ESC 2022

Smartphone-based screening for atrial fibrillation (eBRAVE-AF) – A pragmatic siteless digital randomized clinical trial

Presenter: Axel Bauer

August 28, 2022

More slides +

Presentation ESC 2022

Coronary Atherosclerotic Plaque Activity and Future Coronary Events

Presenter: David Newby

August 28, 2022

Presentation ESC 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presenter: Sanjit Jolly

August 28, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.